ArticleThe Structural Basis for the Binding of Repaglinide (cas 108157-52-4) to the Pancreatic KATP Channel

Add time:08/22/2019    Source:sciencedirect.com

SummaryRepaglinide (cas 108157-52-4) (RPG) is a short-acting insulin secretagogue widely prescribed for the treatment of type 2 diabetes. It boosts insulin secretion by inhibiting the pancreatic ATP-sensitive potassium channel (KATP). However, the mechanisms by which RPG binds to the KATP channel are poorly understood. Here, we describe two cryo-EM structures: the pancreatic KATP channel in complex with inhibitory RPG and adenosine-5’-(γ-thio)-triphosphate (ATPγS) at 3.3 Å and a medium-resolution structure of a RPG-bound mini SUR1 protein in which the N terminus of the inward-rectifying potassium channel 6.1 (Kir6.1) is fused to the ABC transporter module of the sulfonylurea receptor 1 (SUR1). These structures reveal the binding site of RPG in the SUR1 subunit. Furthermore, the high-resolution structure reveals the complex architecture of the ATP binding site, which is formed by both Kir6.2 and SUR1 subunits, and the domain-domain interaction interfaces.

We also recommend Trading Suppliers and Manufacturers of Repaglinide (cas 108157-52-4). Pls Click Website Link as below: cas 108157-52-4 suppliers

Prev:Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[11C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors
Next:Endocrine pharmacologyCharacteristics of Repaglinide (cas 108157-52-4) effects on insulin secretion)